<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medvis</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская визуализация</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Visualization</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-0763</issn><issn pub-type="epub">2408-9516</issn><publisher><publisher-name>RDS-Media Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24835/1607-0763-2020-2-96-97</article-id><article-id custom-type="elpub" pub-id-type="custom">medvis-916</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>COVID-19</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COVID-19</subject></subj-group></article-categories><title-group><article-title>КТ-семиотика пневмонии у пациентов с COVID-19, получающих терапию тоцилизумабом: обзор зарубежной литературы</article-title><trans-title-group xml:lang="en"><trans-title>CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab: foreign literature review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7349-1192</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сташкив</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Stashkiv</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сташкив Владислава Ивановна – ординатор </p><p>117997 Москва, ул. Большая Серпуховская, д. 27</p></bio><bio xml:lang="en"><p>Vladislava I. Stashkiv – Resident</p><p>117997, Moscow, Bolshaya Serpukhovskaya str., 27</p></bio><email xlink:type="simple">vladastashkiv@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1643-6613</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Замятина</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zamyatina</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Замятина Ксения Андреевна – ординатор </p><p>117997 Москва, ул. Большая Серпуховская, д. 27</p><p> </p></bio><bio xml:lang="en"><p>Kseniia A. Zamyatina – Resident</p><p>117997, Moscow, Bolshaya Serpukhovskaya str., 27</p></bio><email xlink:type="simple">catos-zama@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4518-4451</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шантаревич</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shantarevich</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шантаревич Мария Юрьевна – ординатор</p><p>117997 Москва, ул. Большая Серпуховская, д. 27</p></bio><bio xml:lang="en"><p>Mariia Yu. Shantarevich – Resident</p><p>117997, Moscow, Bolshaya Serpukhovskaya str., 27</p></bio><email xlink:type="simple">shantarevichm@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никитина</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikitina</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никитина Ирина Викторовна – ординатор</p><p>117997 Москва, ул. Большая Серпуховская, д. 27</p></bio><bio xml:lang="en"><p>Irina V. Nikitina – Resident</p><p>117997, Moscow, Bolshaya Serpukhovskaya str., 27</p></bio><email xlink:type="simple">i9100841940@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9357-0998</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кармазановский</surname><given-names>Г. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kаrmаzаnovsky</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кармазановский Григорий Григорьевич – член-корр. РАН, доктор мед. наук, профессор, заведующий отделением рентгенологии и магнитно-резонансных исследований с кабинетом ультразвуковой диагностики; профессор кафедры лучевой диагностики и терапии медико-биологического факультета</p><p>117997 Москва, ул. Большая Серпуховская, д. 27</p></bio><bio xml:lang="en"><p>Grigory G. Kаrmаzаnovsky – Corresponding member of the Russiаn Асаdemy of Sсienсes, Dr. of Sci. (Med.), Professor, Heаd of X-ray and magnetic resonance studies department with ultrasound; Professor of radiology department</p><p>117997, Moscow, Bolshaya Serpukhovskaya str., 27</p></bio><email xlink:type="simple">karmazanovsky@ixv.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1791-9163</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ревишвили</surname><given-names>А. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Revishvili</surname><given-names>A. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ревишвили Амиран Шотаевич – академик РАН, доктор мед. наук, профессор, директор</p><p>117997 Москва, ул. Большая Серпуховская, д. 27</p></bio><bio xml:lang="en"><p>Amiran Sh. Revishvili – Academician of the Russian Academy of Science, Dr. of Sci. (Med.), Professor, Director</p><p>117997, Moscow, Bolshaya Serpukhovskaya str., 27</p></bio><email xlink:type="simple">amirevi@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ “Национальный медицинский исследовательский центр хирургии имени А.В. Вишневского” Минздрава России<country>Россия</country></aff><aff xml:lang="en">A.V. Vishnevsky Medical Research Center of Surgery the Ministry of Health of the Russian Federation of the Ministry of Health of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>06</month><year>2020</year></pub-date><volume>24</volume><issue>2</issue><issue-title>Медицинская визуализация 2020№2</issue-title><fpage>96</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сташкив В.И., Замятина К.А., Шантаревич М.Ю., Никитина И.В., Кармазановский Г.Г., Ревишвили А.Ш., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Сташкив В.И., Замятина К.А., Шантаревич М.Ю., Никитина И.В., Кармазановский Г.Г., Ревишвили А.Ш.</copyright-holder><copyright-holder xml:lang="en">Stashkiv V.I., Zamyatina K.A., Shantarevich M.Y., Nikitina I.V., Kаrmаzаnovsky G.G., Revishvili A.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medvis.vidar.ru/jour/article/view/916">https://medvis.vidar.ru/jour/article/view/916</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: обзор и анализ имеющейся зарубежной литературы, посвященной КТ-семиотике COVID-19-пневмонии у пациентов, получающих в качестве патогенетической терапии тоцилизумаб.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Проанализировано 6 публикаций, которые были доступны по ключевым словам “COVID-19”, “radiology”, “CT”, “tocilizumab”, “сytokine release syndrome”, “interleukin 6”, “IL-6”. Поиск ограничивался только рукописями на английском языке без ограничения по времени. Последний раз поиск литературы проводился 3 июня 2020 г.</p></sec><sec><title>Результаты</title><p>Результаты. На сегодняшний день существует небольшое количество исследований, посвященных КТ-семиотике COVID-19-пневмонии при лечении актемрой (тоцилизумабом). По запросу “COVID-19”, “radiology”, “CT”, “tocilizumab”, “сytokine release syndrome”, “interleukin 6”, “IL-6” в базе данных медицинских и биологических публикаций “PubMed” на 03.06.2020 можно найти только 8 публикаций, которые удовлетворяли бы поисковому запросу, из них только 1 полнотекстовая статья, целью которой было исследование КТ-семиотики COVID-19-пневмонии у пациентов, получающих в качестве терапии тоцилизумаб. Важно отметить, что новые данные распространяются регулярно, и до сих пор они состоят в основном из препринтов, кейсов, отчетов, небольших клинических случаев.</p></sec><sec><title>Заключение</title><p>Заключение. Проанализировав имеющуюся литературу, можно сделать вывод, что подавляющее число авторов подтверждают положительный эффект, связанный с приемом тоцилизумаба, о чем свидетельствует очень быстрое улучшение состояния больных. Однако КТ-картина часто не коррелирует с клиническим течением заболевания и не всегда демонстрирует улучшение по картине легких, что должно расцениваться не как отрицательная динамика, а как естественный регресс патологических изменений легочной ткани, который может занимать некоторое количество времени.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose. Review and analysis of the available foreign literature about CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab.</p></sec><sec><title>Material and methods</title><p>Material and methods. 6 publications were analyzed that were available for the keywords “COVID-19”, “radiology”, “CT”, “tocilizumab”, “cytokine release syndrome”, “interleukin 6”, “IL-6”. Search was limited only to English language manuscripts with no time limit. The literature search was last done on 3rd June 2020.</p></sec><sec><title>Results</title><p>Results. There is a small number of studies on CT findings of COVID-19 pneumonia during the treatment of actemra (tocilizumab). At the request of “COVID-19”, “radiology”, “CT”, “tocilizumab”, “cytokine release syndrome”, “interleukin 6”, “IL-6” in the database of medical and biological publications “PubMed” on 03.06.2020 can be found only 8 publications that would satisfy the search query. At the time of writing this article we were able to locate only 1 full text articles in English which was the study of CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab. It is important to note that new data is being shared regularly and so far, it consists mostly of pre-prints, case reports, small case series.</p></sec><sec><title>Conclusion</title><p>Conclusion. After analyzing the available literature, it can be concluded that the majority of authors confirm the positive effect associated with taking tocilizumab, as evidenced by a very rapid improvement in the condition of patients, however, the CT-findings often does not correlate with the clinical course of the disease and does not always show improvement in lung tissue, which should not be regarded as negative dynamics, but as a natural regression of pathological changes in lung tissue.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>тоцилизумаб</kwd><kwd>КТ</kwd><kwd>ИЛ-6</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>CT</kwd><kwd>tocilizumab</kwd><kwd>IL-6</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T., Li P., Zhou Y., Lin Y.F., Duan Q., Luo G., Fan S., Lu Y., Feng A., Zhan Y., Liang B., Cai W., Zhang L., Du X., Li L., Shu Y., Zou H. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and metaanalysis. J. Infect. 2020; 80 (6): 656–665. https://doi.org/10.1016/j.jinf.2020.03.041.</mixed-citation><mixed-citation xml:lang="en">Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T., Li P., Zhou Y., Lin Y.F., Duan Q., Luo G., Fan S., Lu Y., Feng A., Zhan Y., Liang B., Cai W., Zhang L., Du X., Li L., Shu Y., Zou H. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and metaanalysis. J. Infect. 2020; 80 (6): 656–665. https://doi.org/10.1016/j.jinf.2020.03.041.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">WHO main website. http://www.euro.who.int/ru/healthtopics/health-emergencies/coronavirus-covid-19 (accessed March 12, 2020)</mixed-citation><mixed-citation xml:lang="en">WHO main website. http://www.euro.who.int/ru/healthtopics/health-emergencies/coronavirus-covid-19 (accessed March 12, 2020)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Лучевая диагностика коронавирусной болезни (COVID-19): организация, методология, интерпретация результатов. Препринт № ЦДТ – 2020 – II Версия 2 (17.04.2020). Текст: электронный.</mixed-citation><mixed-citation xml:lang="en">Radiology of coronavirus disease (COVID-19): organization, methodology, interpretation of results. Preprint No. CDT – 2020 – II Version 2 (17.04.2020). Text: electronic. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment of COVID-19 [published online ahead of print, 2020 Mar 28]. Int. J. Antimicrob. Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105955</mixed-citation><mixed-citation xml:lang="en">Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment of COVID-19 [published online ahead of print, 2020 Mar 28]. Int. J. Antimicrob. Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105955</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации профилактики, диагностики и лечения новой коронавирусной инфекции (COVID-19) Минздрава РФ. Версия 6 от 28.04.2020.</mixed-citation><mixed-citation xml:lang="en">Temporary guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19), Ministry of Health of the Russian Federation version 6 of 28.04.2020. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Xia L. Coronavirus Disease 2019 (COVID-19): role of chest CT in diagnosis and management. Am. J. Roentgenol. 2020; 214 (6): 1280–1286. https://doi.org/10.2214/AJR.20.22954</mixed-citation><mixed-citation xml:lang="en">Li Y., Xia L. Coronavirus Disease 2019 (COVID-19): role of chest CT in diagnosis and management. Am. J. Roentgenol. 2020; 214 (6): 1280–1286. https://doi.org/10.2214/AJR.20.22954</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.rosminzdrav.ru/ministry/med_covid19 Recommendations for doctors on Covid-19 of the Ministry of Health of the Russian Federation.</mixed-citation><mixed-citation xml:lang="en">https://www.rosminzdrav.ru/ministry/med_covid19 Recommendations for doctors on Covid-19 of the Ministry of Health of the Russian Federation.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19. 2020; 10 (Google Scholar)</mixed-citation><mixed-citation xml:lang="en">Chen J. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19. 2020; 10 (Google Scholar)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Xie Z., Lin W., Cai W., Wen C. et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). [online]. Website https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2 [accessed 12 April 2020].</mixed-citation><mixed-citation xml:lang="en">Li Y., Xie Z., Lin W., Cai W., Wen C. et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). [online]. Website https://www.medrxiv.org/content/10.1 101/2020.03.19.20038984v2 [accessed 12 April 2020].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Young B.E., Ong S.W.X., Kalimuddin S., Low J.G., Tan S.Y. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020; 10 [PMC free article] [PubMed] [Google Scholar]</mixed-citation><mixed-citation xml:lang="en">Young B.E., Ong S.W.X., Kalimuddin S., Low J.G., Tan S.Y. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020; 10 [PMC free article] [PubMed] [Google Scholar]</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C.Y., Wang F.L., Lin C.C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin. Toxicology. 2006; 44: 173– 175. https://doi.org/10.1080/15563650500514558</mixed-citation><mixed-citation xml:lang="en">Chen C.Y., Wang F.L., Lin C.C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin. Toxicology. 2006; 44: 173– 175. https://doi.org/10.1080/15563650500514558</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Borba M.G.S., De Almeida Val F., Sampaio V.S., Araújo Alexandre M.A., Melo G.C. et al. Chloroquine diphosphate in two different dosages as adjunctive therapy ofhospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study) [online]. (2020). https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2 [accessed 12 April 2020]</mixed-citation><mixed-citation xml:lang="en">Borba M.G.S., De Almeida Val F., Sampaio V.S., Araújo Alexandre M.A., Melo G.C. et al. Chloroquine diphosphate in two different dosages as adjunctive therapy ofhospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study) [online]. (2020). https://www.medrxiv.org/content/10.11 01/2020.04.07.20056424v2 [accessed 12 April 2020]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chorin E., Dai M., Shulman E., Wadhwani L., Cohen R.B. et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin [online]. 2020. https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1 [accessed 12 April 2020].</mixed-citation><mixed-citation xml:lang="en">Chorin E., Dai M., Shulman E., Wadhwani L., Cohen R.B. et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin [online]. 2020. https://www.medrxiv.org/content/10.1101/2020.0 4.02.20047050v1 [accessed 12 April 2020].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22: S0140-6736(20)31180-6. https://doi.org/10.1016/S0140-6736(20)31180-6. Epub ahead of print. Erratum in: Lancet. 2020 May 30: PMID: 32450107; PMCID: PMC7255293.</mixed-citation><mixed-citation xml:lang="en">Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22: S0140-6736(20)31180-6. https://doi.org/10.1016/S0140-6736(20)31180-6. Epub ahead of print. Erratum in: Lancet. 2020 May 30: PMID: 32450107; PMCID: PMC7255293.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ministry of Health of the Russian Federation “On the use of the drug Hydroxychloroquine for the treatment of patients with coronavirus infection” dated May 28, 2020. https://www.rosminzdrav.ru/news/2020/05/28/14067-oprimenenii-preparata-gidroksihlorohin-dlya-lecheniyapatsientov-s-koronavirusnoy-infektsiey</mixed-citation><mixed-citation xml:lang="en">Ministry of Health of the Russian Federation “On the use of the drug Hydroxychloroquine for the treatment of patients with coronavirus infection” dated May 28, 2020. https://www.rosminzdrav.ru/news/2020/05/28/14067-oprimenenii-preparata-gidroksihlorohin-dlya-lecheniyapatsientov-s-koronavirusnoy-infektsiey</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chu C.M., Cheng V.C., Hung I.F.N., Wong M.M., Chan K.H. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252–256. https://doi.org/10.1136/thorax.2003.012658</mixed-citation><mixed-citation xml:lang="en">Chu C.M., Cheng V.C., Hung I.F.N., Wong M.M., Chan K.H. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252–256. https://doi.org/10.1136/thorax.2003.012658</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ye X.T., Luo Y.L., Xia S.C., Sun Q.F., Ding J.G., Zhou Y., Chen W., Wang X.F., Zhang W.W., Du W.J., Ruan Z.W., Hong L. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur. Rev. Med. Pharmacol. Sci. 2020; 24 (6): 3390–3396. https://doi.org/10.26355/eurrev_202003_20706. PMID: 32271456.</mixed-citation><mixed-citation xml:lang="en">Ye X.T., Luo Y.L., Xia S.C., Sun Q.F., Ding J.G., Zhou Y., Chen W., Wang X.F., Zhang W.W., Du W.J., Ruan Z.W., Hong L. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur. Rev. Med. Pharmacol. Sci. 2020; 24 (6): 3390–3396. https://doi.org/10.26355/eurrev_202003_20706. PMID: 32271456.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Assessment Report For RoActemra [Internet] 1st ed. London: European Medicines Agency; 2009. [accessed 2017January3]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_ report/human/000955/WC500054888.pdf</mixed-citation><mixed-citation xml:lang="en">Assessment Report For RoActemra [Internet] 1st ed. London: European Medicines Agency; 2009. [accessed 2017January3]. http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Public_assessment_ report/human/000955/WC500054888.pdf</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.roche.ru/content/dam/rochexx/roche-ru/roche_russia/ru_RU/Instructions/actemra-iv-2019-12-30.pdf Версия 10 МИНЗДРАВ РОССИИ ЛСР-003012/09-301219</mixed-citation><mixed-citation xml:lang="en">https://www.roche.ru/content/dam/rochexx/roche-ru/roche_russia/ru_RU/Instructions/actemra-iv-2019-12-30.pdf Версия 10 МИНЗДРАВ РОССИИ ЛСР-003012/09-301219</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Higuchi T., Nakanishi T., Takada K., Matsumoto M., Okada M., Horikoshi H., Suzuki K. A case of multicentric castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, Tocilizumab. J. Korean Med. Sci. 2010; 25 (9): 1364–1367. https://doi.org/10.3346/jkms.2010.25.9.1364. PMID:20808682.</mixed-citation><mixed-citation xml:lang="en">Higuchi T., Nakanishi T., Takada K., Matsumoto M., Okada M., Horikoshi H., Suzuki K. A case of multicentric castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, Tocilizumab. J. Korean Med. Sci. 2010; 25 (9): 1364–1367. https://doi.org/10.3346/jkms.2010.25.9.1364. PMID:20808682.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-andtocilizumab-cytokine-release-syndrome</mixed-citation><mixed-citation xml:lang="en">FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. https://www. fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-andtocilizumab-cytokine-release-syndrome</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473–474. https://doi.org/10.1126/science.abb8925</mixed-citation><mixed-citation xml:lang="en">Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473–474. https://doi.org/10.1126/science.abb8925</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Le R.Q., Li L., Yuan W., Shord S.S., Nie L., Habtemariam B.A., Przepiorka D., Farrell A.T., Pazdurb R. Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018; 23 (8): 943–947. https://doi.org/10.1634/theoncologist.2018-0028</mixed-citation><mixed-citation xml:lang="en">Le R.Q., Li L., Yuan W., Shord S.S., Nie L., Habtemariam B.A., Przepiorka D., Farrell A.T., Pazdurb R. Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018; 23 (8): 943–947. https://doi.org/10.1634/theoncologist.2018-0028</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan J., Zou R., Zeng L. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm. Res. 2020 Mar 29: 1–8. https://doi.org/10.1007/s00011-020-01342-0</mixed-citation><mixed-citation xml:lang="en">Yuan J., Zou R., Zeng L. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm. Res. 2020 Mar 29: 1–8. https://doi.org/10.1007/s00011-020-01342-0</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang C., Wu Z., Li J.W., Zhao H., Wang G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and Inter leukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents. 2020:105954. https://doi.org/10.1016/j.ijantimicag.2020.105954.</mixed-citation><mixed-citation xml:lang="en">Zhang C., Wu Z., Li J.W., Zhao H., Wang G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and Inter leukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents. 2020:105954. https://doi.org/10.1016/j.ijantimicag.2020.105954.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of 2019 novel coronavirus infection in China. Med. Rxiv. 2019;2020:2020. https://doi.org/10.1101/2020.02.06.20020974</mixed-citation><mixed-citation xml:lang="en">Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of 2019 novel coronavirus infection in China. Med. Rxiv. 2019;2020:2020. https://doi.org/10.1101/2020.02.06.20020974</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.rosminzdrav.ru/ministry/med_covid19</mixed-citation><mixed-citation xml:lang="en">https://www.rosminzdrav.ru/ministry/med_covid19</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn. Interv. Imaging. 2020; 101 (5): 323–324. https://doi.org/10.1016/j.diii.2020.03.010.</mixed-citation><mixed-citation xml:lang="en">Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn. Interv. Imaging. 2020; 101 (5): 323–324. https://doi.org/10.1016/j.diii.2020.03.010.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Xu X., Han M., Li T., Sun W., Wang D., Fu B., Zhou Y., Zheng X., Yang Y., Li X., Zhang X., Pan A., Wei H. Effective Treatment of Severe COVID-19 Patients With Tocilizumab. Proc. Natl. Acad. Sci. USA. 2020; 117 (20): 10970–10975. https://doi.org/10.1073/pnas.2005615117</mixed-citation><mixed-citation xml:lang="en">Xu X., Han M., Li T., Sun W., Wang D., Fu B., Zhou Y., Zheng X., Yang Y., Li X., Zhang X., Pan A., Wei H. Effective Treatment of Severe COVID-19 Patients With Tocilizumab. Proc. Natl. Acad. Sci. USA. 2020; 117 (20): 10970–10975. https://doi.org/10.1073/pnas.2005615117</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Michot J.-M., Albiges L., Chaput N., Saada V., Pommeret F., Griscelli F., Balleyguier C., Besse B., Marabelle A., Netzer F., Merad M., Robert C., Barlesi F., Gachot B., Stoclin A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann. Oncol. 2020 Apr 2: S0923-7534(20)36387-0. https://doi.org/10.1016/j.annonc.2020.03.300</mixed-citation><mixed-citation xml:lang="en">Michot J.-M., Albiges L., Chaput N., Saada V., Pommeret F., Griscelli F., Balleyguier C., Besse B., Marabelle A., Netzer F., Merad M., Robert C., Barlesi F., Gachot B., Stoclin A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann. Oncol. 2020 Apr 2: S0923-7534(20)36387-0. https://doi.org/10.1016/j.annonc.2020.03.300</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Peng X., Wang Z.-H., Cai J., Zhou F.-C. Tocilizumab in the treatment of a critical COVID-19 patient: a case report. Eur. Rev. Med. Pharmacol. Sci. 2020; 24 (10): 5783–5787. https://doi.org/10.26355/eurrev_202005_21372</mixed-citation><mixed-citation xml:lang="en">Wang L., Peng X., Wang Z.-H., Cai J., Zhou F.-C. Tocilizumab in the treatment of a critical COVID-19 patient: a case report. Eur. Rev. Med. Pharmacol. Sci. 2020; 24 (10): 5783–5787. https://doi.org/10.26355/eurrev_202005_21372</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Mihai C., Dobrota R., Schröder M., Garaiman A., Jordan S., Becker M.O., Maurer B., Distler O. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann. Rheum. Dis. 2020; 79 (5): 668–669. https://doi.org/10.1136/annrheumdis-2020-217442</mixed-citation><mixed-citation xml:lang="en">Mihai C., Dobrota R., Schröder M., Garaiman A., Jordan S., Becker M.O., Maurer B., Distler O. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann. Rheum. Dis. 2020; 79 (5): 668–669. https://doi.org/10.1136/annrheumdis-2020-217442</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">The first affiliated hospital of university of science and technology. The efficacy and safety of tocilizumab in the treatment of novel coronavirus pneumonia: a multi-center, randomized, double-blinded trial. 2020. https://www.chictr.org.cn/showproj.aspx?proj=49409. Accessed 22 Feb 2020.</mixed-citation><mixed-citation xml:lang="en">The first affiliated hospital of university of science and technology. The efficacy and safety of tocilizumab in the treatment of novel coronavirus pneumonia: a multi-center, randomized, double-blinded trial. 2020. https://www. chictr.org.cn/showproj. aspx?proj=49409. Accessed 22 Feb 2020.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
